Daiichi Sankyo Europe, Gmbh, A Daiichi Sankyo Company

This study follows about 1,155 adults with HER2-low breast cancer that has spread or cannot be removed by surgery. It compares how long patients stay on a new targeted drug (trastuzumab deruxtecan) versus standard chemotherapy before needing a different treatment. The goal is to …

This study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will observe how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, includin…

This study looks at how well a three-medicine combination works for people with very high cholesterol who are at high risk for heart problems. About 2000 adults will take bempedoic acid plus ezetimibe and a statin. Researchers will check cholesterol levels after 8 weeks and 1 yea…